ArticlePharmaceutical research2010
Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles.
Article in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 85 citations in OpenAlex.
- Target-Product and Translational Design Principles for Inhalable RNA Nanomedicines.Pharmaceutics · 2026Review
- Chitosan siRNA Nanoparticles Produce Significant Non-Toxic Functional Gene Silencing in Kidney Cortices.Polymers · 2024Article
- The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy.Pharmaceutics · 2024Review
- Impact of Peptide Sequence on Functional siRNA Delivery and Gene Knockdown with Cyclic Amphipathic Peptide Delivery Agents.Molecular pharmaceutics · 2023Article
- Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside.Pharmaceutics · 2022Review
- siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?Advanced healthcare materials · 2021Review
- Fundamental and Practical Aspects in the Formulation of Colloidal Polyelectrolyte Complexes of Chitosan and siRNA.Methods in molecular biology (Clifton, N.J.) · 2021Review
- RNAi therapeutic strategies for acute respiratory distress syndrome.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Recent Advances in Chitosan-Based Carriers for Gene Delivery.Marine drugs · 2019Review
- Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA.Drug delivery · 2018Article
- Polymers in the Delivery of siRNA for the Treatment of Virus Infections.Topics in current chemistry (Cham) · 2017Review
- Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.Kona : powder science and technology in Japan · 2016Article
- Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.Current pharmaceutical design · 2015Review
- siRNA delivery to the lung: what's new?Advanced drug delivery reviews · 2014Review
- Chitosans for delivery of nucleic acids.Advanced drug delivery reviews · 2013Review
- Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs.Acta naturae · 2013Article
- Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles.Molecular therapy. Nucleic acids · 2013Article
- RNAi Therapeutic Platforms for Lung Diseases.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Clinical translation of RNAi-based treatments for respiratory diseases.Drug delivery and translational research · 2013Article
- Flow cytometry-based cell type-specific assessment of target regulation by pulmonary siRNA delivery.Methods in molecular biology (Clifton, N.J.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis work describes the production and application of an aerosolised formulation of chitosan nanoparticles for improved pulmonary siRNA delivery and gene silencing in mice.
methodsAerosolised chitosan/siRNA nanoparticles were pneumatically formed using a nebulising catheter and sized by laser diffraction. In vitro silencing of aerosolised and non-aerosolised formulations was evaluated in an EGFP endogenous-expressing H1299 cell line by flow cytometry. Non-invasive intratracheal insertion of the catheter was used to study nanoparticle deposition by histological detection of Cy3-labeled siRNA and gene silencing in transgenic EGFP mouse lungs using a flow cytometric method.
resultsFlow cytometric analysis demonstrated minimal alteration in gene silencing efficiency before (68%) and after (62%) aerosolisation in EGFP-expressing H1299 cells. Intratracheal catheter administration in mice resulted in nanoparticle deposition throughout the entire lung in both alveoli and bronchiolar regions using low amounts of siRNA. Transgenic EGFP mice dosed with the aerosolised nanoparticle formulation showed significant EGFP gene silencing (68% reduction compared to mismatch group).
conclusionsThis work provides a technology platform for effective pulmonary delivery and gene silencing of RNAi therapeutics with potential use in preclinical studies of respiratory disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.